Glaukos Corporation Files Registration Statement for Proposed Initial Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. In connection with the proposed IPO, Glaukos has applied to list its common stock on The New York Stock Exchange under the symbol "GKOS".

J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. William Blair and Cantor Fitzgerald & Co. are acting as co-managers for the offering.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: (866) 803-9204; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email [email protected]; or Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or email at [email protected].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of any offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Glaukos

Glaukos Corporation (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. Glaukos launched iStent Trabecular Micro-Bypass Stent, the industry's first Micro-Invasive Glaucoma Surgery (MIGS) device, in the United States in 2012. The company is based in Laguna Hills, CA.

Glaukos Corporation
Richard Harrison, Chief Financial Officer, 949-367-9600 ext 223
[email protected]

Source: Glaukos Corporation

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Vertex (VERX) Reports Prelim Q1 Results
• Scorpius Holdings (SCPX) Receives Nasdaq Filing Delinquency Notification